[Prevalence of anti-hepatitis A in patients with chronic liver disease].
The recent availability of an effective vaccine for preventing hepatitis A has led to the performance of a prevalence study of antibodies versus the hepatitis A virus (HAV) in our patients with chronic liver disease by hepatitis B and C, as a step prior to vaccination. The sera of 425 patients with a mean age of 40 years was studied, with the global antibodies versus HAV being determined (Abbott). The prevalence was to 75.2% varying from 20% at 19 years to 93% in those over the age of 40. The prevalence was not related to sex, previous parenteral history, or drug addiction or infection by hepatitis B or C. Due to previous cost-benefit studies and the high prevalence found, the determination of anti-HAV in patients with chronic viral liver diseases prior to vaccination against HAV is recommended.
Diago
M
M
Servicio de Digestivo, Hospital General Universitario, Valencia.
Luján
M
M
García
V
V
Cors
R
R
Carbonell
P
P
Tuset
C
C
Gimeno
J
J
D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D006506:Hepatitis A / Q000175:diagnosis / Q000517:prevention & control*; D006508:Hepatitis Antibodies / Q000097:blood*; D019694:Hepatitis B, Chronic / Q000276:immunology / Q000821:virology*; D019698:Hepatitis C, Chronic / Q000276:immunology / Q000821:virology*; D006507:Hepatovirus / Q000276:immunology*; D006801:Humans; D008297:Male; D016036:Seroepidemiologic Studies; D014611:Vaccination; D014761:Viral Hepatitis Vaccines
D006508:Hepatitis Antibodies; D014761:Viral Hepatitis Vaccines